The clinical assets to be acquired include cancer and ocular disease programs, including regulatory and clinical packages and access to Oncotelic's AI platform for identifying immunotherapy combinations HUNTINGTON BEACH, CA / ACCESSWIRE / April 29, 2024 / Mosaic ImmunoEngineering, Inc. ("Mosaic" or the "Company"), (OTC PINK:CPMV), a development-stage biotechnology company focused on the development of novel immunotherapies... Read More

Issued patents include important claims covering methods of treating cancer using MIE-101 as a single agent or in combination with other treatment modalities MIE-101 has demonstrated potent, durable, and systemic antitumor activity in multiple preclinical tumor models and in naturally occurring canine tumors NOVATO, CA / ACCESSWIRE / April 11, 2023 / Mosaic ImmunoEngineering, Inc. ("Mosaic" or the "Company"), (OTCQB:CPMV), a... Read More